Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,271
Views
19
CrossRef citations to date
0
Altmetric
Back Matter

Establishment and validation of an immunodiagnostic model for prediction of breast cancer

Cuipeng Qiua Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China;b College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, ChinaORCID Iconhttps://orcid.org/0000-0002-3956-0430View further author information
ORCID Icon,
Peng Wanga Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China;b College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
,
Bofei Wangb College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
,
Jianxiang Shib College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, China;c Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
,
Xiao Wangb College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, China;c Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
,
Tiandong Lia Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China;b College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, ChinaORCID Iconhttps://orcid.org/0000-0002-5465-9797View further author information
ORCID Icon,
Jiejie Qina Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China;b College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
,
Liping Daib College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, China;c Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
,
Hua Yea Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China;b College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3657-2417View further author information
ORCID Icon &
Jianying Zhanga Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China;b College of Public Health, Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou, Henan, China;c Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 1682382 | Received 06 Aug 2019, Accepted 14 Oct 2019, Published online: 28 Oct 2019

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–11. PMID:30207593. doi:10.3322/caac.21492.
  • Lacombe J, Mange A, Solassol J. Use of autoantibodies to detect the onset of breast cancer. J Immunol Res . 2014;2014:574981. PMID:25143958. doi:10.1155/2014/574981.
  • Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005. PMID:23171096. doi:10.1056/NEJMoa1206809.
  • Fernández-Madrid F, Maroun M-C, Autoantibodies in breast cancer. Adv Clin Chem. 2014;64:221–240. doi: 10.1016/b978-0-12-800263-6.00005-7.
  • Qaseem A, J S L, Mustafa RA, Horwitch CA, Wilt TJ. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann Intern Med. 2019. PMID:30959525. doi:10.7326/M18-2147
  • Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van ‘t Riet M, et al. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncol. 2019;20:1136–1147. doi:10.1016/s1470-2045(19)30275-x.
  • Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer: tumor Size and overdiagnosis. Ann Intern Med. 2017;166(5). PMID:28114656. doi:10.7326/p16-9029.
  • Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18(5):868–873. PMID:17347129. doi:10.1093/annonc/mdm007.
  • Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2(3):210–219. PMID:11990857. doi:10.1038/nrc755.
  • Chen YT, Gure AO, Scanlan MJ. Serological analysis of expression cDNA libraries (SEREX): an immunoscreening technique for identifying immunogenic tumor antigens. Methods Mol Med. 2005; 207–216. PMID:15542909.
  • Zhu Q, Liu M, Dai L, Ying X, Ye H, Zhou Y, Han S, Zhang J-Y. Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2013;12(12):1123–1128. PMID:23806562. doi:10.1016/j.autrev.2013.06.015.
  • Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang J-Y. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2011;10(6):331–335. PMID:21167321. doi:10.1016/j.autrev.2010.12.002.
  • Bassaro L, Russell SJ, Pastwa E, Somiari SA, Somiari RI. Screening for multiple autoantibodies in plasma of patients with breast cancer. Cancer Genomics Proteomics. 2017;14(6):427–435. PMID:29109092.
  • Li P, Shi J-X, Dai L-P, Chai Y-R, Zhang H-F, Kankonde M, Kankonde P, Yu B-F, Zhang J-Y. Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer. Oncoimmunology. 2016;5(5):e1138200. PMID:27467958. doi:10.1080/2162402x.2016.1138200.
  • Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev . 2008;222:328–340. PMID:18364012. doi:10.1111/j.1600-065X.2008.00611.x.
  • Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. Febs J. 2009;276(23):6880–6904. PMID:19860826. doi:10.1111/j.1742-4658.2009.07396.x.
  • Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer . 2018;92:54–68. PMID:29413690. doi:10.1016/j.ejca.2017.12.025.
  • Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982;30(4):403–408. PMID:6292117. doi:10.1002/(ISSN)1097-0215.
  • Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60(7):1777–1788. PMID:10766157.
  • Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem. 1999;45(5):630–637. PMID:10222349.
  • Klee GG, Schreiber WE. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med. 2004;128(10):1131–1135. PMID:15387710. doi:10.1043/1543-2165(2004)128<1131:mggafm>2.0.co;2.
  • Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, Blixt O, Fourkala EO, Bueti D, Dawnay A, et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. Br J Cancer. 2013;108(10):2045–2055. PMID:23652307. doi:10.1038/bjc.2013.214.
  • Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res. 2005;11(4):1521–1526. PMID:15746055. doi:10.1158/1078-0432.ccr-04-0538.
  • Xiu Y, Sun B, Jiang Y, Wang A, Liu L, Liu Y, Sun S, Huangfu Ml. Diagnostic value of the survivin autoantibody in four types of malignancies. Genet Test Mol Biomarkers. 2018;22(6):384–389. PMID:29924656. doi:10.1089/gtmb.2017.0278.
  • Cao J, Mu Q, Huang H. The roles of insulin-like growth Factor 2 mRNA-binding protein 2 in cancer and cancer stem cells. Stem Cells Int . 2018;2018:4217259. PMID:29736175. doi:10.1155/2018/4217259.
  • Liu W, De La Torre IG, Gutierrez-Rivera MC, Wang B, Liu Y, Dai L, Qian W, Zhang J-Y. Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Tumour Biol. 2015;36(2):1307–1312. PMID:25355596. doi:10.1007/s13277-014-2756-5.
  • Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, Li CI, Prentice R, Hanash SM, Disis ML, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila). 2012;5(8):1036–1043. PMID:22715141. doi:10.1158/1940-6207.capr-11-0558.
  • Qin J, Wang S, Wang P, Wang X, Ye H, Song C, Dai L, Wang K, Jiang B, Zhang J, et al. Autoantibody against 14-3-3 zeta: a serological marker in detection of gastric cancer. J Cancer Res Clin Oncol. 2019;145(5):1253–1262. PMID:30887154. doi:10.1007/s00432-019-02884-5.
  • Wang S, Qin J, Ye H, Wang K, Shi J, Ma Y, Duan Y, Song C, Wang X, Dai L, et al. Using a panel of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of gastric cancer. Oncoimmunology. 2018;7(8):e1452582. PMID:30221047. doi:10.1080/2162402X.2018.1452582.
  • Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, Qian W, Zhang J. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett. 2013;5(2):663–668. PMID:23420714. doi:10.3892/ol.2012.1062.
  • Wang P, Qin J, Ye H, Li L, Wang X, Zhang J. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer. J Cell Biochem. 2019;120(3):3091–3100. PMID:30484895. doi:10.1002/jcb.27497.
  • Dai L, Ren P, Liu M, Imai H, Tan EM, Zhang J-Y. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. Clin Immunol. 2014;152(1–2):127–139. PMID:24667685. doi:10.1016/j.clim.2014.03.007.
  • Koziol JA, Imai H, Dai L, Zhang J-Y, Tan EM. Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens. Cancer Immunol Immunother. 2018;67(5):835–841. PMID:29497780. doi:10.1007/s00262-018-2135-y.
  • Qin J, Wang S, Shi J, Ma Y, Wang K, Ye H, Zhang X, Wang P, Wang X, Song C, et al. Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma. Cancer Sci. 2019. PMID:30950146. doi:10.1111/cas.14013
  • Zhang Y, Ying X, Han S, Wang J, Zhou X, Bai E, Zhang J,Zhu Q. Autoantibodies against insulin-like growth factor-binding protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol. 2013;42(1):93–100. PMID:23165420. doi:10.3892/ijo.2012.1699.
  • Xu Y-W, Peng Y-H, Chen B, Wu Z-Y, Wu J-Y, Shen J-H, Zheng C-P, Wang S-H, Guo H-P, Li E-M, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2014;109(1):36–45. PMID:24296751. doi:10.1038/ajg.2013.384.
  • Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK,Tan EM, et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003;12(2):136–143. PMID:12582023.
  • Liu Y, Liao Y, Xiang L, Jiang K, Li S, Huangfu M, Sun S. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer. Int J Clin Oncol. 2017;22(2):291–296. PMID:27778118. doi:10.1007/s10147-016-1047-0.
  • Tsentidis C, Bampilis A, Ntova V, Fragkos D, Liu Y, Liao Y, Xiang L, Jiang K, Li S, Huangfu M, et al. Metabolic syndrome as a predictor of adrenal functional status: a discriminant multivariate analysis versus logistic regression analysis. Horm Metab Res. 2019;51(1):47–53. PMID:30406628. doi:10.1055/a-0754-6464.
  • Zou M, Sun C, Liang S, Sun Y, Li D, Li L, Fan L, Wu L, Xia W. Fisher discriminant analysis for classification of autism spectrum disorders based on folate-related metabolism markers. J Nutr Biochem. 2019;64:25–31. PMID:30419423. doi:10.1016/j.jnutbio.2018.09.023.
  • Goncalves-Ribeiro S, Sanz-Pamplona R, Vidal A, Sanjuan X, Guillen Díaz-Maroto N, Soriano A, Guardiola J, Albert N, Martínez-Villacampa M, López I, et al. Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. Ann Oncol. 2017;28(9):2160–2168. PMID:28911071. doi:10.1093/annonc/mdx293.
  • Hermann N, Dressen K, Schroeder L, Debald M, Schildberg FA, Walgenbach-Bruenagel G, Hettwer K, Uhlig S, Kuhn W, Hartmann G, et al. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer. Tumour Biol. 2017;39(6):1010428317711381. PMID:28618926. doi:10.1177/1010428317711381.
  • Bayo J, Castano MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. Clin Transl Oncol. 2018;20(4):467–475. PMID:28808872. doi:10.1007/s12094-017-1731-1.
  • Peer PG, Verbeek AL, Straatman H, Hendriks JH, Holland R. Age-specific sensitivities of mammographic screening for breast cancer. Breast Cancer Res Treat. 1996;38(2):153–160. PMID:8861833. doi:10.1007/BF01806669.
  • Looi K, Megliorino R, Shi F-D, Peng -X-X, Chen Y, Zhang J-Y. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 2006;16(5):1105–1110. PMID:17016600.
  • Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471–475. PMID:28813415. doi:10.1038/nature23465.
  • Yan Y, Sun N, Wang H, Kobayashi M, Ladd JJ, Long JP, Lo KC, Patel J, Sullivan E, Albert T, et al. Whole genome-derived tiled peptide arrays detect prediagnostic autoantibody signatures in non-small-cell lung cancer. Cancer Res. 2019;79(7):1549–1557. PMID:30723114. doi:10.1158/0008-5472.CAN-18-1536.
  • Yang L, Wang J, Li J, Zhang H, Guo S, Yan M, Zhu Z, Lan B, Ding Y, Xu M, et al. Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. Mol Cell Proteomics. 2016;15(2):614–623. PMID:26598640. doi:10.1074/mcp.M115.051250.
  • Toes RE, Hitchon CA, Pan J, Song G, Chen D, Li Y, Liu S, Hu S, Rosa C, Eichinger D, et al. Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach. Adv Rheumatol. 2017;16(12):2069–2078. PMID:29021294. doi:10.1002/art.3966410.1074/mcp.RA117.000212.
  • Rho J-H, Ladd JJ, Li CI, Potter JD, Zhang Y, Shelley D, Shibata D, Coppola D, Yamada H, Toyoda H, et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut. 2018;67(3):473–484. PMID:27821646. doi:10.1136/gutjnl-2016-312794.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.